LifeCell Corporation Invites You to Join its First Quarter 2001 Conference Call

Apr 26, 2001, 01:00 ET from LifeCell Corporation

    BRANCHBURG, N.J., April 26 /PRNewswire/ -- In conjunction with LifeCell
 Corporation's First Quarter 2001 Earnings Release, Paul G. Thomas, Chairman,
 President and CEO of LifeCell Corporation will be hosting a conference call on
 Thursday, May 3, 2001 at 11:00 AM EDT.  A listen-only, live webcast of the
 conference call will be available at
 http://www.videonewswire.com/LIFECELL/050301.  (Minimum requirements to listen
 to the webcast: The RealPlayer software, downloadable free from
 http://www.real.com/products/player/index.html, and at least a 14.4Kbps
 connection to the Internet.)
 
     What:  LifeCell Corporation First Quarter 2001 Earnings Release
            Conference Call
 
     When:  11:00 AM EDT, Thursday, May 3, 2001
 
     Conference Call Information
 
      Call-in #:    800-540-0559
 
      Access Code:  LifeCell
 
      Replay #:     800-938-1602 -- Available approximately 2 hours after
                                    event ends (from 5/3/01 through 5/10/01).
 
      Contact:      Steven Sobieski, VP, CFO, 908-947-1106
 
     LifeCell Corporation is a leader in the emerging field of regenerative
 medicine engaged in developing and marketing biologic solutions for the
 repair, replacement and preservation of human tissues.  The Company's core
 technology removes all cells from the tissue and preserves the tissue without
 damaging the essential biochemical and structural components necessary for
 normal tissue regeneration.  LifeCell currently markets three human tissue
 products based on its technology: AlloDerm(R) for plastic reconstructive and
 burn procedures through LifeCell's direct sales force and for periodontal
 procedures through BioHorizons, Inc.; Cymetra(TM), a version of AlloDerm in
 particulate form for the correction of soft tissue defects, through LifeCell's
 direct sales force and a co-promotion agreement with Obagi Medical Products,
 Inc; and Repliform(TM), a version of AlloDerm for urology and gynecology
 procedures, through the Company's partnership with Boston Scientific
 Corporation.  LifeCell's development programs include the application of its
 technology to process small diameter blood vessel grafts as an alternative to
 blood vessel grafts taken from the patient, investigation of potential
 orthopedic applications of its technology, investigation of human tissues as
 carriers for therapeutics, Thrombosol(TM), a formulation for extended storage
 of platelets and technologies to enhance the storage of red blood cells for
 transfusion.
     If you are unable to Participate during the live webcast, the call will he
 archived on the Web site http://www.LifeCell.com/financial.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X99346359
 
 

SOURCE LifeCell Corporation
    BRANCHBURG, N.J., April 26 /PRNewswire/ -- In conjunction with LifeCell
 Corporation's First Quarter 2001 Earnings Release, Paul G. Thomas, Chairman,
 President and CEO of LifeCell Corporation will be hosting a conference call on
 Thursday, May 3, 2001 at 11:00 AM EDT.  A listen-only, live webcast of the
 conference call will be available at
 http://www.videonewswire.com/LIFECELL/050301.  (Minimum requirements to listen
 to the webcast: The RealPlayer software, downloadable free from
 http://www.real.com/products/player/index.html, and at least a 14.4Kbps
 connection to the Internet.)
 
     What:  LifeCell Corporation First Quarter 2001 Earnings Release
            Conference Call
 
     When:  11:00 AM EDT, Thursday, May 3, 2001
 
     Conference Call Information
 
      Call-in #:    800-540-0559
 
      Access Code:  LifeCell
 
      Replay #:     800-938-1602 -- Available approximately 2 hours after
                                    event ends (from 5/3/01 through 5/10/01).
 
      Contact:      Steven Sobieski, VP, CFO, 908-947-1106
 
     LifeCell Corporation is a leader in the emerging field of regenerative
 medicine engaged in developing and marketing biologic solutions for the
 repair, replacement and preservation of human tissues.  The Company's core
 technology removes all cells from the tissue and preserves the tissue without
 damaging the essential biochemical and structural components necessary for
 normal tissue regeneration.  LifeCell currently markets three human tissue
 products based on its technology: AlloDerm(R) for plastic reconstructive and
 burn procedures through LifeCell's direct sales force and for periodontal
 procedures through BioHorizons, Inc.; Cymetra(TM), a version of AlloDerm in
 particulate form for the correction of soft tissue defects, through LifeCell's
 direct sales force and a co-promotion agreement with Obagi Medical Products,
 Inc; and Repliform(TM), a version of AlloDerm for urology and gynecology
 procedures, through the Company's partnership with Boston Scientific
 Corporation.  LifeCell's development programs include the application of its
 technology to process small diameter blood vessel grafts as an alternative to
 blood vessel grafts taken from the patient, investigation of potential
 orthopedic applications of its technology, investigation of human tissues as
 carriers for therapeutics, Thrombosol(TM), a formulation for extended storage
 of platelets and technologies to enhance the storage of red blood cells for
 transfusion.
     If you are unable to Participate during the live webcast, the call will he
 archived on the Web site http://www.LifeCell.com/financial.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X99346359
 
 SOURCE  LifeCell Corporation